Therefore, we performed further experiments to explore the role of high-concentration PGD2 in drug response to venetoclax, which was the inhibitor of Bcl-2 and displayed greatly anti-tumor effects in hematological cancers. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.